113 related articles for article (PubMed ID: 3659571)
1. Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man.
Tokuma Y; Fujiwara T; Noguchi H
Res Commun Chem Pathol Pharmacol; 1987 Aug; 57(2):229-37. PubMed ID: 3659571
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective disposition of nilvadipine, a new dihydropyridine calcium antagonist, in the rat and dog.
Tokuma Y; Fujiwara T; Niwa T; Hashimoto T; Noguchi H
Res Commun Chem Pathol Pharmacol; 1989 Feb; 63(2):249-62. PubMed ID: 2711027
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats.
Bohlooli S; Keyhanfar F; Mahmoudian M
Biopharm Drug Dispos; 2004 May; 25(4):187-91. PubMed ID: 15108221
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of nilvadipine after single oral doses in healthy volunteers.
Cheung WK; Woodward DL; Shin K; Hibberd M; Pearse S; Desjardins RE; Yacobi A; Silber BM
Int J Clin Pharmacol Res; 1988; 8(5):299-305. PubMed ID: 3229870
[TBL] [Abstract][Full Text] [Related]
5. Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs.
Tokuma Y; Fujiwara T; Noguchi H
Xenobiotica; 1987 Nov; 17(11):1341-9. PubMed ID: 3433803
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human.
Teramura T; Watanabe T; Higuchi S; Hashimoto K
Xenobiotica; 1995 Nov; 25(11):1237-46. PubMed ID: 8592872
[TBL] [Abstract][Full Text] [Related]
7. Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers.
Terakawa M; Tokuma Y; Kuwahara N; Shishido A; Noguchi H
J Clin Pharmacol; 1988 Apr; 28(4):350-5. PubMed ID: 3392233
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of nilvadipine.
von Nieciecki A; Huber HJ; Stanislaus F
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S22-9. PubMed ID: 1283185
[TBL] [Abstract][Full Text] [Related]
9. Determination of (+)- and (-)-nilvadipine in human plasma using chiral stationary-phase liquid chromatography and gas chromatography-mass spectrometry, and a preliminary pharmacokinetic study in humans.
Tokuma Y; Fujiwara T; Noguchi H
J Pharm Sci; 1987 Apr; 76(4):310-3. PubMed ID: 3598890
[TBL] [Abstract][Full Text] [Related]
10. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.
Saima S; Furuie K; Yoshimoto H; Fukuda J; Hayashi T; Echizen H
Br J Clin Pharmacol; 2002 Feb; 53(2):203-6. PubMed ID: 11851646
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats, rabbits and dogs.
Tokuma Y; Sekiguchi M; Niwa T; Noguchi H
Xenobiotica; 1988 Jan; 18(1):21-8. PubMed ID: 3354229
[TBL] [Abstract][Full Text] [Related]
12. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
Fornasini G; Monti N; Brogin G; Gallina M; Eandi M; Persiani S; Bani M; Della Pepa C; Zara G; Strolin Benedetti M
Chirality; 1997; 9(3):297-302. PubMed ID: 9176996
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma nilvadipine concentration after single and chronic oral administration to patients with chronic liver disease.
Takata Y; Yoshizumi T; Ito Y; Kikuchi M; Ueno M; Tsukashima A; Kobayashi K; Fujishima M
Eur J Clin Pharmacol; 1992; 42(5):475-9. PubMed ID: 1606993
[TBL] [Abstract][Full Text] [Related]
14. Circadian variations in the pharmacokinetics, tissue distribution and urinary excretion of nifedipine after a single oral administration to rats.
Cao QR; Kim TW; Choi JS; Lee BJ
Biopharm Drug Dispos; 2005 Dec; 26(9):427-37. PubMed ID: 16217814
[TBL] [Abstract][Full Text] [Related]
15. Nilvadipine: profile of a new calcium antagonist. An overview.
Rosenthal J
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
[TBL] [Abstract][Full Text] [Related]
16. Food interaction pharmacokinetic study of cordaflex 20 mg retard filmtablet in healthy volunteers.
Balogh Nemes K; Horváth V; Grézal G; Horvai G; Hrabéczy-Páll A; Kocsi E; Drabant S; Csörgö M; Renczes G; Klebovich I
Int J Clin Pharmacol Ther; 1998 May; 36(5):263-9. PubMed ID: 9629990
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two marketed nifedipine modified-release formulations: an exploratory clinical food interaction study.
Wonnemann M; Schug B; Anschütz M; Brendel E; De Nucci G; Blume H
Clin Ther; 2008 Jan; 30(1):48-58. PubMed ID: 18343242
[TBL] [Abstract][Full Text] [Related]
18. Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog.
Wu WH; Henderson BM; Lanc R; Garnes D; Yacobi A; Silber BM
Drug Metab Dispos; 1988; 16(2):222-7. PubMed ID: 2898337
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective oxidation and plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man.
Niwa T; Tokuma Y; Nakagawa K; Noguchi H; Yamazoe Y; Kato R
Res Commun Chem Pathol Pharmacol; 1988 May; 60(2):161-72. PubMed ID: 3393731
[TBL] [Abstract][Full Text] [Related]
20. Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog.
Niwa T; Tokuma Y; Noguchi H
Res Commun Chem Pathol Pharmacol; 1987 Jan; 55(1):75-88. PubMed ID: 3563108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
